a-922500 and Weight-Loss

a-922500 has been researched along with Weight-Loss* in 1 studies

Other Studies

1 other study(ies) available for a-922500 and Weight-Loss

ArticleYear
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
    Journal of medicinal chemistry, 2008, Feb-14, Volume: 51, Issue:3

    A highly potent and selective DGAT-1 inhibitor was identified and used in rodent models of obesity and postprandial chylomicron excursion to validate DGAT-1 inhibition as a novel approach for the treatment of metabolic diseases. Specifically, compound 4a conferred weight loss and a reduction in liver triglycerides when dosed chronically in DIO mice and depleted serum triglycerides following a lipid challenge in a dose-dependent manner, thus, reproducing major phenotypical characteristics of DGAT-1(-/-) mice.

    Topics: Animals; Anti-Obesity Agents; Biphenyl Compounds; Cycloheptanes; Diacylglycerol O-Acyltransferase; Eating; Humans; Hypolipidemic Agents; Isoenzymes; Keto Acids; Liver; Mice; Mice, Mutant Strains; Stereoisomerism; Structure-Activity Relationship; Triglycerides; Urea; Weight Loss

2008